biostudies-literatureUnknown325(1)Wang X<h4>Importance</h4>Among all subtypes of breast cancer, triple-negative breast cancer has a relatively high relapse rate and poor outcome after standard treatment. Effective strategies to reduce the risk of relapse and death are needed.<h4>Objective</h4>To evaluate the efficacy and adverse effects of low-dose capecitabine maintenance after standard adjuvant chemotherapy in early-stage triple-negative breast cancer.<h4>Design, setting, and participants</h4>Randomized clinical trial conducted at 13 academic centers and clinical sites in China from April 2010 to December 2016 and final date of follow-up was April 30, 2020. Patients (n = 443) had early-stage triple-negative breast cancer and had completed standard adjuvant chemotherapy.<h4>Interventions</h4>Eligible patients were randomized 1:JAMA50-58https://www.ebi.ac.uk/biostudies/studies/S-EPMC7729589biostudies-literatureEffect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.PMC7729589Peng RJLi JBXue CGuo YHuang HHe ZYShi WCai LLin YBi XWJiang KKTang JZhao LWang XMSouth China Breast Cancer Group (SCBCG)An XWang XWang XYHua XHuang JJHuang ZZSong CGZhang LHShi YXPang DMXu FSu YHYuan ZYXia WHong RXLiu XMChen QJZhang AQLin HXKe YLCao YZeng JWang SSZhong YYfalseEffect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.<h4>Importance</h4>Among all subtypes of breast cancer, triple-negative breast cancer has a relatively high relapse rate and poor outcome after standard treatment. Effective strategies to reduce the risk of relapse and death are needed.<h4>Objective</h4>To evaluate the efficacy and adverse effects of low-dose capecitabine maintenance after standard adjuvant chemotherapy in early-stage triple-negative breast cancer.<h4>Design, setting, and participants</h4>Randomized clinical trial conducted at 13 academic centers and clinical sites in China from April 2010 to December 2016 and final date of follow-up was April 30, 2020. Patients (n = 443) had early-stage triple-negative breast cancer and had completed standard adjuvant chemotherapy.<h4>Interventions</h4>Eligible patients were randomized 1:2021-01-01T00:00:00Z2021 Jan2026-05-02T00:56:04.713Z2022-02-10T14:19:36.576ZS-EPMC77295893330095010.1001/jama.2020.23370